Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsNatalia Kunst, PhD
Assistant Professor AdjunctAbout
Research
Publications
2025
Cost‐effectiveness of low‐dose CT lung cancer screening among individuals that have ever smoked in Norway: A model‐based analysis using NELSON trial criteria and outcomes
Wu Y, Kunst N, Győrbiró D, Kristiansen I, Strand T, Nguyen O, Fotopoulos I, Røe O, Ashraf H, Burger E. Cost‐effectiveness of low‐dose CT lung cancer screening among individuals that have ever smoked in Norway: A model‐based analysis using NELSON trial criteria and outcomes. International Journal Of Cancer 2025 PMID: 41414902, DOI: 10.1002/ijc.70270.Peer-Reviewed Original ResearchLow-dose computed tomographyQuality-adjusted life yearsLung cancer screeningIncremental cost-effectiveness ratioLDCT screeningCancer screeningCost-effectiveness of LDCT screeningLow-dose computed tomography lung cancer screeningHealth-related quality-of-life dataLung cancer screening programCancer screening programCT lung cancer screeningLung cancer mortalityLow-dose CT lung cancer screeningTrial outcomesHealth benefitsScreening-related outcomesQuality-of-life dataCost-effectiveNELSON trialScreening implementationCancer mortalityNo screeningSex-stratifiedEver-smokersEffectiveness and Cost-Effectiveness of Automated External Defibrillators in Private Homes
Andersen L, Holmberg M, Krijkamp E, Stankovic N, Meilandt C, Vallentin M, Høybye M, Folke F, Kunst N, Dijk S, Granfeldt A, Caulley L. Effectiveness and Cost-Effectiveness of Automated External Defibrillators in Private Homes. JAMA Internal Medicine 2025, 186 PMID: 41137600, PMCID: PMC12554008, DOI: 10.1001/jamainternmed.2025.6123.Peer-Reviewed Original ResearchAutomated external defibrillator applicationAutomated external defibrillatorShockable rhythmCardiac arrestExternal defibrillatorsAutomated external defibrillator useEffect of automated external defibrillatorsPrivate homesHospital dischargeCardiac Arrest RegistryCardiac arrest incidenceDifference-in-differences analysisCost-effectiveIncremental cost-effectiveness ratioGeneral purchasersCost-effectiveness thresholdArrest incidenceMain OutcomesCost-effectiveness ratioNonshockable rhythmsCohort studyDecision-analytic modelDifference-in-differences approachHomeSaving livesProstate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival
Gogebakan K, Elsisi Z, Montano‐Campos F, Owens L, Zhao Y, Gulati R, Ferdinandus J, Fendler W, Calais J, Hope T, Carlsson S, Fainberg J, Laudone V, Kunst N, Berlin A, Schipper M, Barbour A, Iravani A, Etzioni R. Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival. Cancer 2025, 131: e70131. PMID: 41108673, PMCID: PMC12632154, DOI: 10.1002/cncr.70131.Peer-Reviewed Original ResearchConceptsRadical prostatectomyBiochemical recurrenceIncremental life-yearsProstate-specific Membrane Antigen Positron Emission Tomography/Computed TomographyHazard ratioPositron Emission Tomography/Computed TomographyLife yearsPositron emission tomography/computed tomography imagingHealth-related qualityEmission Tomography/Computed TomographyLong-term treatment benefitsProstate cancer recurrenceDisease-specific deathManagement of patientsLong-term outcomesProgression to metastasisLong-term survivalPostmetastasis survivalPSMA PET/CTSalvage regimensSystemic regimensDecision-analytic modelSalvage treatmentTomography/Computed TomographySurvival benefitCost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation
Kunst N, Long J, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation. JAMA Network Open 2025, 8: e2539250. PMID: 41134573, PMCID: PMC12552925, DOI: 10.1001/jamanetworkopen.2025.39250.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsPSMA-PETBiochemical recurrenceProstate cancerProstate-specific membrane antigen positron emission tomographyLow prostate-specific antigen levelsBiochemically recurrent prostate cancerProstate-specific antigen levelMetastatic prostate cancerProstate cancer evaluationStudy of patientsUS academic centersLifetime quality-adjusted life yearsTreatment costsCost-effectiveness ratioPositron emission tomographyDecision-analytic modelDefinitive surgeryRadiation therapyMolecular imagingAntigen levelsBone scanPatient subsetsReflex testLong-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study
Andersen M, Kunst N, Richman I. Long-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study. Value In Health 2025 PMID: 40983310, DOI: 10.1016/j.jval.2025.09.005.Peer-Reviewed Original ResearchBreast cancer screeningQuality-adjusted life yearsBreast cancer deathsBreast cancer casesCancer screeningIncremental cost-effectiveness ratioDigital breast tomosynthesisBreast Cancer Surveillance ConsortiumCancer casesLong-term health outcomesBreast cancer mortalityCancer deathNegative screeningNationally representative dataCost-effectiveBiennial screeningAdvanced breast cancer casesHealth outcomesCancer mortalityCost-effectiveness ratioWomen ageStandardized screeningLife yearsRepresentative dataRoutine practiceModeling the Impact of Multicancer Early Detection Tests: A Review of Natural History of Disease Models
Mandrik O, Whyte S, Kunst N, Rayner A, Harden M, Dias S, Payne K, Palmer S, Soares M. Modeling the Impact of Multicancer Early Detection Tests: A Review of Natural History of Disease Models. Medical Decision Making 2025, 45: 1013-1024. PMID: 40753481, PMCID: PMC12511643, DOI: 10.1177/0272989x251351639.Peer-Reviewed Original ResearchMulticancer early detectionNatural history of diseaseHistory of diseaseTrial evidenceMulticancer early detection testsAbsence of trial evidenceScreening clinical trialsCancer screening modelStage shiftEarly detection testsEarly detectionCritical appraisalNatural historyMortality impactClinical study evidenceMortality effectsTest accuracyCost-effectiveEvaluation approachClinical studiesClinical trialsPublished estimatesMortalityAppraisalStudy evidenceCost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States.
Potnis K, Ito S, Kunst N, Richman I, Winer E, Goshua G. Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States. Journal Of Clinical Oncology 2025, 43: 11049-11049. DOI: 10.1200/jco.2025.43.16_suppl.11049.Peer-Reviewed Original ResearchHER2- early breast cancerEarly breast cancerIncremental cost-effectiveness ratioEndocrine therapyBreast cancerQuality-adjusted life yearsDeterministic sensitivity analysisHR-positiveHER2-negative early breast cancerWTP thresholdCost-effectiveness of ribociclibInvasive disease-free survivalDisease-free survival curvesAcceptable WTP thresholdDisease-free survivalBase-caseHigher WTP thresholdNonsteroidal aromatase inhibitorBase-case analysisCyclin-dependent kinase 4Cost-effectiveness ratioHER2-negativeCDK4/6 inhibitorsAromatase inhibitorsHealth system perspectiveAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original ResearchProstate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients With Biochemically Recurrent Prostate Cancer
Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Kunst N, Wang S, Ma X, Gross C, Leapman M, Karnes R. Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients With Biochemically Recurrent Prostate Cancer. JU Open Plus 2025, 3 DOI: 10.1097/ju9.0000000000000278.Peer-Reviewed Original ResearchMetastasis-directed therapyPSMA PET findingsPSMA-PETBiochemical recurrencePSA levelsDistant metastasisProstate cancerLocal therapyProstate-specific membrane antigen positron emission tomographyClinical managementBiochemically recurrent prostate cancerIdentification of distant metastasesNegative PSMA-PETRecurrent prostate cancerRegional nodal diseasePositron emission tomographyNodal diseaseLocal recurrenceInitial therapySystemic therapyTreatment initiationClinical outcomesImaging findingsMetastasisTreatment choiceExamining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria
Donoghue J, Youngs M, Reeve A, Vydyula K, Kunst N, Trikha R, Gallacher D. Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria. PharmacoEconomics 2025, 43: 499-508. PMID: 39934600, PMCID: PMC12011644, DOI: 10.1007/s40273-025-01472-5.Peer-Reviewed Original ResearchSingle Technology AppraisalNational Institute for Health and Care ExcellenceTechnology appraisalCost-effectiveness evidenceParoxysmal nocturnal haemoglobinuriaEconomic modelExamination consistAppraisalCare ExcellenceHealth technologiesFollow-up lengthImplementation of health technologyIndirect comparisonsDose escalationCost-effective healthcareEvidenceClinical evidencePositive recommendations